Boehringer Ingelheim Extends Scope of Collaboration with Evotec into Screening Services

New agreements signed with Boehringer Ingelheim Germany and Canada

04-Nov-2005

Evotec AG announced that Boehringer Ingelheim (Boehringer) has extended the scope of its collaboration with Evotec. In addition to the substantial discovery programme to jointly identify and develop therapeutics acting on G-Protein Coupled Receptors (GPCRs) Boehringer research sites in Biberach (Germany) and Laval (Canada) will now collaborate with Evotec under a fee-for-service agreement.

For selected Boehringer target proteins, Evotec will apply its skills in biochemical and cellular assay development as well as in ultra-high-throughput screening (uHTS) using its proprietary FCS+plus detection platform to rapidly and accurately identify promising hit molecules from Boehringer's and Evotec's compound libraries. Active compounds will be further progressed by Boehringer to develop novel treatments for different diseases.

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

MBL scientists find genes linked to human neurological disorders in sea lamprey genome - Discovery will accelerate research on Alzheimer's disease, Parkinson's disease and spinal cord injury

Merck Proposes the Creation of a Global Alliance for the Elimination of Schistosomiasis

Positive Results in Proof-of-Concept Study with Sustained Release Treatment for Uveitis

Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan - Abbott will retain its branded generics pharmaceuticals business in emerging markets

Stanford researchers explore link between human birth defect syndrome, cancer metastasis

Asia-Pacific continues to drive global healthcare investment, innovation and growth ASEAN - A US$150 billion healthcare market by 2017, says Frost & Sullivan

Pharmacogenomics study finds rare gene variants critical for personalized drug treatment

Cambridge-based Startup Develops World’s Fastest Coronavirus-Killing Antiviral Protection

Cambridge-based Startup Develops World’s Fastest Coronavirus-Killing Antiviral Protection

Evolva shareholders approve all Board proposals in AGM: Green light for Abunda acquisition

Aragen Bioscience, Inc. and CEVEC Sign License Agreement for Human CAP and CAP-T Technology

Synthetic chemistry approach yields new compounds with potential biomedical applications - The study marks a significant advancement in chemical synthesis techniques, leveraging modern organic chemistry and engineered enzymes

Synthetic chemistry approach yields new compounds with potential biomedical applications - The study marks a significant advancement in chemical synthesis techniques, leveraging modern organic chemistry and engineered enzymes